Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACRS 
Aclaris Therapeutics Inc (ACRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ACRS (3-star) is a STRONG-BUY. BUY since 10 days. Profits (-1.60%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.86
1 Year Target Price $7.86
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 53.72% | Avg. Invested days 27 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.33M USD | Price to earnings Ratio - | 1Y Target Price 7.86 |
Price to earnings Ratio - | 1Y Target Price 7.86 | ||
Volume (30-day avg) 6 | Beta 0.31 | 52 Weeks Range 1.05 - 5.17 | Updated Date 08/29/2025 |
52 Weeks Range 1.05 - 5.17 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.14 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -951.49% |
Management Effectiveness
Return on Assets (TTM) -20.86% | Return on Equity (TTM) -101.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 80651281 | Price to Sales(TTM) 11.87 |
Enterprise Value 80651281 | Price to Sales(TTM) 11.87 | ||
Enterprise Value to Revenue 4.8 | Enterprise Value to EBITDA 0.28 | Shares Outstanding 108332000 | Shares Floating 72651919 |
Shares Outstanding 108332000 | Shares Floating 72651919 | ||
Percent Insiders 2.69 | Percent Institutions 86.19 |
Upturn AI SWOT
Aclaris Therapeutics Inc
Company Overview
History and Background
Aclaris Therapeutics, Inc. was founded in 2012 and is a biopharmaceutical company focusing on developing novel treatments for immuno-inflammatory diseases.
Core Business Areas
- Immuno-inflammatory Diseases: Development and commercialization of therapies for dermatological and other immuno-inflammatory conditions.
Leadership and Structure
The company is led by a management team with experience in dermatology and drug development. Its organizational structure consists of functional departments such as R&D, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- Zunreza (retosiban): A selective MEK 1/2 inhibitor being developed for hidradenitis suppurativa (HS). No current market share data available as it's still in development. Competitors include Humira (adalimumab) and other biologics used off-label.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation and competition, with a focus on new therapies for unmet medical needs, especially in immuno-inflammatory diseases where personalized medicine and biologics are significant trends.
Positioning
Aclaris is positioned as a specialty pharmaceutical company focused on immuno-inflammatory conditions, seeking to develop novel treatments through targeted therapies. Their success depends on the clinical trial results and regulatory approvals of their lead compounds.
Total Addressable Market (TAM)
The global market for immuno-inflammatory diseases is projected to reach billions of dollars. Aclaris aims to capture a portion of this TAM through the development and commercialization of targeted therapies.
Upturn SWOT Analysis
Strengths
- Focused pipeline on immuno-inflammatory diseases
- Novel MEK inhibitor technology
- Experienced management team
Weaknesses
- Limited commercialized products
- Reliance on successful clinical trial outcomes
- High cash burn rate
Opportunities
- Expanding into new immuno-inflammatory indications
- Partnerships and collaborations for development
- Potential for FDA approval and market entry
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Generic erosion of existing products
Competitors and Market Share
Key Competitors
- ABBV
- LLY
- MRK
Competitive Landscape
Aclaris faces significant competition from larger pharmaceutical companies with established portfolios and greater resources. Their success depends on the differentiation and efficacy of their pipeline assets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on successful clinical trials and commercialization.
Future Projections: Future projections are speculative and depend on analyst forecasts.
Recent Initiatives: Focus on clinical development of Zunreza and other pipeline assets.
Summary
Aclaris Therapeutics is a clinical-stage biopharmaceutical company with a focus on immuno-inflammatory diseases. Its lead asset, Zunreza, holds promise, but the company faces significant risks associated with clinical development and competition. With limited product revenues, cash management is key. Future success will depend on positive clinical trial results and the ability to secure regulatory approvals and commercial partnerships. Investors should monitor clinical trial updates and financial performance closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may be subject to change. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclaris Therapeutics Inc
Exchange NASDAQ | Headquaters Wayne, PA, United States | ||
IPO Launch date 2015-10-07 | Co-Founder, CEO & Chairman Dr. Neal S. Walker D.O., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.aclaristx.com |
Full time employees 61 | Website https://www.aclaristx.com | ||
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.